Genezen

Genezen sought to assess how biopharmaceutical companies and payor organizations, predominantly in North America, Europe, and Asia, are navigating reimbursement negotiations for commercial cell and gene therapies through a targeted survey. The survey engaged those in clinical development leadership and executive management, shedding light on the impact reimbursement strategies have on developmental pipelines and investor attitudes. The resulting report informed Genezen’s teams to engage with innovators more effectively and tailor its technology stack to changing demands.
Your Shortcut to Smarter Life-Sciences Decisions
Let’s discuss how Nice Insight’s market research and pricing intelligence can deliver actionable insights for your business.